Neridronic Acid

Summary

Neridronic Acid (CHEMBL55214) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including complex regional pain syndrome and osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 277.15 Da · C6H17NO7P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL55214
Name	Neridronic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	71237
Molecular formula	C6H17NO7P2
Molecular weight	277.15
InChIKey	PUUSSSIBPPTKTP-UHFFFAOYSA-N

SMILES: C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN

IUPAC name: (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid

Also known as: Acide neridronique, Acido neridronico, Ahhexbp, Neridronate, Neridronic acid, NERIDRONIC ACID, NERIDRONATE SODIUM SALT, Neridronate Sodium Salt

Patent coverage: 2,883 distinct patent families (11,356 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Farnesyl pyrophosphate synthase.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FDPS	7.2	Ki	63.5	nM	CHEMBL_ACT_2155093
FDPS	6.41	IC50	388.2	nM	CHEMBL_ACT_2155092
FDPS	6.38	Ki	415.7	nM	CHEMBL_ACT_2155049
FDPS	6.36	Ki	440	nM	CHEMBL_ACT_1091333
FDPS	5.62	IC50	2427	nM	CHEMBL_ACT_2155048
FDPS	5.34	IC50	4600	nM	CHEMBL_ACT_1091332
FDPS	5.34	IC50	4571	nM	CHEMBL_ACT_1091334

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
complex regional pain syndrome	3	MONDO:0019369	EFO:1001998
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07210515	PHASE3	RECRUITING	Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
NCT02402530	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I
NCT02972359	PHASE3	COMPLETED	Safety of Intravenous Neridronic Acid in CRPS
NCT03530345	PHASE3	TERMINATED	Efficacy and Safety of Intravenous Neridronic Acid in CRPS
NCT03560986	PHASE3	TERMINATED	Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)
NCT01140321	PHASE2	COMPLETED	Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI
NCT01803360	PHASE2	UNKNOWN	Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).